linjc16/ctgov huggingface dataset:
GENOA ORAL GROWTH LONGITUDINAL STUDY (GeOrGS)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to follow a group of preschool children from early permanent dentition to determine the prevalence and incidence of caries malocclusions and to investigated the related risk factors as age, gender, ethnic origin and non-nutritive sucking habits, breathing disturbances, allergies, Dietary habits, oral hygiene status and dental care.

Detailed Description
-----------------
Once a year a clinical examination were performed. Data were collected with a questionnaire, that was filled out by the parents before the clinical examination, which included questions on child's clinical history, the type of feeding, the use of baby-bottle, the history of non-nutritive sucking habits (dummy-sucking and digit sucking) and the consent to the clinical examination. Two World Health Organization (WHO) calibrated examiners carried out the clinical examinations. They were blinded to the information collected from the parental questionnaires. Dental examinations were performed in a classroom environment under natural light, using gloves and masks in compliance with the infection control protocol, mouth mirrors and disposable paper rulers to measure overjet and overbite (in millimeters). The occlusion was assessed in centric occlusion and was classified according to Foster and Hamilton criteria [Foster and Hamilton, 1969] Radiographic examination was not performed.

Official Title
-----------------
GENOA ORAL GROWTH STUDY: Longitudinal Investigation of Preschool and Primary School Children

Conditions
-----------------
Malocclusion, Dental Caries

Intervention / Treatment
-----------------
* Other: Clinical dental examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children born in 2008 and 2009 in Chiavari District (Italy) Exclusion Criteria: parents' lack of consent absence at the date of the visit; no compliance orthodontic treatment; marked occlusal wear or early loss of primary teeth alterations in the number, size and shape of teeth syndromes or systemic problems affecting craniofacial growth cleft palate.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GeOrGS cohort<br>Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy) | Other: Clinical dental examination<br>* Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence (rate %) of Malocclusions and Caries |  | longitudinal 3 years |
Pilot Study : FreeStyle Libre Pro Flash Continuous Glucose Monitoring System in Subjects With Diabetes on HemoDIALsis

Study Overview
=================
Brief Summary
-----------------
Continuous monitoring of glucose with a FreeStyle Libre pro sensor in diabetic and dialysis patients

Official Title
-----------------
FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System in Subjects With Diabetes on HemoDIALsis (FSL-DIAL Pilot Study)

Conditions
-----------------
Kidney Failure, Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetes without any change in treatment in the last 3 months Hemodialysis for > 3 months Recent laboratory HbA1c (< 15 days) Exclusion Criteria: Patient does not show non-opposition Skin allergy to the sensor Sepsis / Acute anaemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1c | Comparison between estimated HbA1c with 14 days of CGM data and laboratory HbA1c (routine blood test in hemodialysis) in each subject | At sensor removal (day 14) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time in glucose range | Percent (%) time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L), obtained using professional continuous glucose monitoring (CGM) | At sensor removal (day 14) | 
| Time with Glucose < 70mg/dL | % time with glucose <70 mg/dL | At sensor removal (day 14) | 
| Time with Glucose > 180 mg/dL | % time with glucose >180 mg/dL | At sensor removal (day 14) | 
| Glucose total coefficient of variation (CV) | Glucose total CV (%) | At sensor removal (day 14) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glycemia, diabetes, kidney failure, dialysis, glucose sensor
The Natural History and Outcome of Sleep Disordered Breathing in Children

Study Overview
=================
Brief Summary
-----------------
Sleep-disordered breathing in children is characterized by recurrent events of partial or complete upper airway obstruction during sleep, resulting in disruption of normal gas exchange (intermittent hypoxia and hypercapnia) and sleep fragmentation. The major symptom is snoring or noisy breathing. Sleep Disordered Breathing (SDB) is a wide spectrum of disorders that includes primary snoring, UARS and OSA. The main etiology for SDB in children is enlarged tonsils and adenoids and therefore the first line of treatment in pediatric SDB is adenotonsillectomy. The objectives of this study are: To investigate the natural history of primary snoring To investigate the effect of seasonality on SDB severity To compare the effect of adenoidectomy to adenotonsillectomy in the treatment of SDB in children To characterize the children referred for repeated PSG following adenoidectomy or adenotonsillectomy and the indications for second PSG evaluation.

Official Title
-----------------
The Natural History and Outcome of Sleep Disordered Breathing in Children

Conditions
-----------------
Sleep Disordered Breathing, Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy normally developing children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010 Exclusion Criteria: Chronic medical and neurodevelopmental conditions. Congenital anomalies.

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Winter Vs. Summer<br>All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010 | |
| Primary snoring<br>All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010 | |
| Adenotonsillectomy Vs. Adenoidectomy<br>All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008 | |
| repeated PSG<br>All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Snoring | Snoring will be assesd by PSQ-Pediatric sleep questionnaire | 4 years | 
| OSA severity (AHI, mean SpO2, SPo2 nadir) |  | 4 years | 
| Daytime function | Daytime function will be assesd by PSQ-Pediatric sleep questionnaire | 4 years |
Analysis of Gene Expression in Femoroacetabular Impingement (FAI)

Study Overview
=================
Brief Summary
-----------------
Femoral acetabular impingement (FAI) is a common disease of the hip joint. In this study, whole-genome sequencing was used to further explore the pathogenesis of this disease.

Detailed Description
-----------------
Femoral acetabular impingement (FAI) is a group of chronic hip pain caused by the impact between the proximal femur and the edge of the acetabulum due to the anatomical abnormality of the hip joint, which damages the labrum and adjacent cartilage, and causes limited hip movement, especially limited flexion and internal rotation. However, the specific etiology of FAI is still unknown at present. The application of genome-wide, exon and transcription research methods to the study of hip impaction syndrome can uncover key differentially expressed genes and provide a theoretical basis for the study of FAI.

Official Title
-----------------
Total Exon Association Analysis of Femoroacetabular Impingement (FAI)

Conditions
-----------------
Femoroacetabular Impingement

Intervention / Treatment
-----------------
* Other: Exposures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient underwent preoperative imaging and was diagnosed with FAI. The patient complained of pain in the hip, hip, or thigh, and had a positive hip flexion impact test. Exclusion Criteria: Patients with hip surgery history, hip osteoarthritis, necrosis of the femoral head, hip infection, hip dysplasia and other hip diseases.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Exposures|Exposures|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The patients were clinically diagnosed with FAI (femoral acetabular impingement) and underwent arthroscopic surgery, then clinical samples were collected. | Peripheral blood from 100 patients with femoral acetabular impingement syndrome was collected and DNA was extracted. | The patient was diagnosed with FAI, and conservative treatment was ineffective for an average of 6 months. |
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.

Official Title
-----------------
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia

Conditions
-----------------
Dyslipidaemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be 18 years of age or older of either gender or race. Subject must provide informed consent and comply with the survey procedures. Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. Exclusion Criteria: Subjects who are unwilling or unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines |  | 1 visit - 1-3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome |  | 1 visit - 1-3 days | 
| Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome |  | 1 visit - 1-3 days | 
| Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides >200 mg/dL (2.26mmol/L) |  | 1 visit - 1-3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyslipidaemia, LDL-C goals, guidelines
Investigation of the Cylex® ImmuKnow® Assay

Study Overview
=================
Brief Summary
-----------------
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Official Title
-----------------
Investigation of the Cylex® ImmuKnow® Assay

Conditions
-----------------
Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible: Acute leukemia Non-Hodgkin's Lymphoma Chronic lymphocytic leukemia Hodgkin's disease Multiple myeloma Myelodysplastic Syndromes Myeloproliferative Disorders Aplastic Anemia Chronic myelogenous leukemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| observational<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Treatment Resistant Bipolar Depression

Study Overview
=================
Brief Summary
-----------------
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.

Official Title
-----------------
Six Week Double Blind, Randomized Trial of Escitalopram Add On for Treatment Resistant Bipolar Depression

Conditions
-----------------
Bipolar Depression

Intervention / Treatment
-----------------
* Drug: Escitalopram
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or older Diagnosis of Bipolar Disorder and currently be in depressive state, and not responded to mood stabilizer or atypical antipsychotic alone or combined with an antidepressant medication. Exclusion Criteria: Pregnant or breastfeeding History of seizure disorder or other unstable medical condition Received Electroconvulsive Therapy or Transcranial Magnetic Stimulation in the last three months Experienced hallucinations or delusions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine) | Drug: Escitalopram<br>* 10mg to 20mg tablet daily for 6 weeks<br>* Other names: Cipralex;|
| Placebo Comparator: 2<br>to be filled in | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the response rates when Escitalopram vs. placeboes added to the current mood stabilizer or antipsychotic medication |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate efficacy, safety and tolerability of added Escitalopram, to a mood stabilizer or atypical antipsychotic. |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bipolar Depression, Escitalopram, Mood Stabilizer, Atypical Antipsychotic
Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of nitazoxanide suspension in treating diarrhea caused by enteric viruses in children less than 12 years of age.

Official Title
-----------------
Multi-center, Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Conditions
-----------------
Rotavirus Infection, Adenoviridae Infection, Norovirus Infection

Intervention / Treatment
-----------------
* Drug: Alinia (nitazoxanide)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age <12 years. Patients with diarrhea (defined as 3 or more stools per day with liquid or semi-solid consistency, the number and consistency of stools being unusual for that person). Stool positive for adenovirus, norovirus or rotavirus by ELISA. Exclusion Criteria: Females who are pregnant, suspected of being pregnant or breastfeeding. Other identified causes of diarrhea at screening. Serious systemic disorders incompatible with the study.

Ages Eligible for Study
-----------------
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Nitazoxanide<br>7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days | Drug: Alinia (nitazoxanide)<br> <br> |
| Placebo Comparator: Placebo<br>7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days | Drug: Alinia (nitazoxanide)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from first dose to resolution of symptoms. | Median time: 31 hours for nitazoxanide group and 75 hours for the placebo group | P-0.0105 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Virologic response (negative ELISA) at day 7-10. |  |  |
Comparative Study Between Acrylic and Flexible Dentures

Study Overview
=================
Brief Summary
-----------------
comparing the effect of conventional mandibular single denture with flexible mandibular single denture on tissue and patient's satisfaction

Detailed Description
-----------------
comparing the effect of conventional mandibular single denture with flexible mandibular single denture on tissue by keratinization index through PAP stain and patient's satisfaction through a questionnaire

Official Title
-----------------
Comparative Study of Conventional Versus Flexible Mandibular Single Complete Denture

Conditions
-----------------
Health Knowledge, Attitudes, Practice

Intervention / Treatment
-----------------
* Procedure: single conventional denture
* Procedure: single flexible denture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mandibular flat ridge Patient with opposing natural teeth or satisfactory fixed prostheses Angle class I Maxillimandibular relationship No intraoral soft and hard tissue pathosis Non smokers Patients with no previous denture experience Patients having last extraction at least 6 month before denture construction Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single conventional denture<br>patients with mandibular edentulous arch by using acrylic resin denture with soft linner | Procedure: single conventional denture<br>* mandibular conventional denture with soft liner<br>|
| Active Comparator: single flexible denture<br>patients with mandibular edentulous arch by using flexible lower denture | Procedure: single flexible denture<br>* mandibular flexible compete denture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytological changes manifested as keratinization index | Objective Outcome: measuring the cytological changes manifested as keratinization index | 6 months |